Will Genetic Testing Drive Invitae's (NVTA) Q3 Earnings?

Invitae Corporation (NYSE:NVTA) is scheduled to report third-quarter fiscal 2019 results on Nov 6, after market close.

In the last-reported quarter of 2019, the company’s loss per share of 52 cents was wider than the Zacks Consensus Estimate by 8.3%. However, the company delivered a negative earnings surprise in two of the trailing four quarters, the average four-quarter miss being 0.4%.

Let’s take a look at how things are shaping up prior to this announcement.

Factors at Play

Over the last few quarters, genetic testing, one of Invitae’s key business segments, has been consistently delivering robust performance.

Lately, the company has been witnessing a rise in the number of oncology patients undergoing genetic testing. In the last reported quarter, the company accessioned more than 11000 samples for genetic testing, which reflected a 52% year-over-year increase. This trend is expected to have continued in the third quarter.

With the recent launch of its proactive offering, the company has enabled access to genetic testing for a completely new set of customers. This development has led to increased customer adoption and is expected to have driven the top line in the to-be-reported quarter.

The launch of non-invasive prenatal screening (NIPS) using maternal cell-free DNA earlier this year has been strengthening the company’s portfolio of comprehensive women's health genetic testing services. This is expected to show on third-quarter results.

Invitae is focused on widening its genome network and signing biopharma partnerships since the beginning of 2019. Earlier this year, the company expanded its Behind the Seizure program with BioMarin by partnering with two additional companies — Stoke Therapeutics and Xenon Pharmaceuticals. In the last-reported quarter, Invitae acquired Singular Bio and Jungla for technologies to enhance the quality and scale of business. These developments are likely to have contributed to the company’s top line in the third quarter.

Which Way Are Estimates Treading?

Overall, the Zacks Consensus Estimate for total revenues of $55 million implies growth of 47.2% from the prior-year quarter’s reported figure. Also, the consensus mark for a loss of 52 cents is 15.6% wider than the year-ago quarter's reported figure.

Earnings Whispers

Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. That is not the case here as you will see below.

Earnings ESP: Invitae has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: Invitae carries a Zacks Rank #2.

Stocks Worth a Look

Here are a few medical stocks worth considering from the same space with the right mix of elements to surpass expectations this earnings season.

DENTSPLY SIRONA (NASDAQ:XRAY) has an Earnings ESP of +5.05% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

AmerisourceBergen Company (NYSE:ABC) has an Earnings ESP of +0.55% and a Zacks Rank #3.

Cardinal Health (NYSE:CAH) has an Earnings ESP of +0.69% and a Zacks Rank #3.

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

Download Free Report Now >>